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OBJECTIVE
We examined the associations of symptoms of sleep-disordered breathing (SDB),
which was defined as loud snoring, stopping breathing for a while during sleep,
and daytime sleepiness, and insomnia with glucose metabolism and incident
type 2 diabetes in older adults.
RESEARCH DESIGN AND METHODS
Between 1989 and 1993, the Cardiovascular Health Study recruited 5,888 partic-
ipants ‡65 years of age from four U.S. communities. Participants reported SDB
and insomnia symptoms yearly through 1989–1994. In 1989–1990, participants
underwent an oral glucose tolerance test, fromwhich insulin secretion and insulin
sensitivity were estimated. Fasting glucose levels were measured in 1989–1990
and again in 1992–1993, 1994–1995, 1996–1997, and 1998–1999, and medication
use was ascertained yearly. We determined the cross-sectional associations of
sleep symptoms with fasting glucose levels, 2-h glucose levels, insulin sensitivity,
and insulin secretion using generalized estimated equations and linear regression
models. We determined the associations of updated and averaged sleep symp-
toms with incident diabetes in Cox proportional hazards models. We adjusted for
sociodemographics, lifestyle factors, and medical history.
RESULTS
Observed apnea, snoring, and daytime sleepiness were associated with higher
fasting glucose levels, higher 2-h glucose levels, lower insulin sensitivity, and
higher insulin secretion. The risk of the development of type 2 diabetes was
positively associated with observed apnea (hazard ratio [HR] 1.84 [95% CI 1.19–
2.86]), snoring (HR 1.27 [95% CI 0.95–1.71]), and daytime sleepiness (HR 1.54 [95%
CI 1.13–2.12]). In contrast, we did not find consistent associations between in-
somnia symptoms and glucose metabolism or incident type 2 diabetes.
CONCLUSIONS
Easily collected symptoms of SDB are strongly associated with insulin resistance
and the incidence of type 2 diabetes in older adults. Monitoring glucose metab-
olism in such patients may prove useful in identifying candidates for lifestyle or
pharmacological therapy. Further studies are needed to determine whether in-
somnia symptoms affect the risk of diabetes in younger adults.
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Sleep disorders are increasingly recognized
as important factors in glucose metabolism
and the development of type 2 diabetes.
Sleep-disordered breathing (SDB), a condi-
tion characterized by a reduction or com-
plete cessation of airflow during sleep, has
repeatedly been linked to impaired glucose
tolerance and insulin resistance in clinic-
based studies (1,2) and, more recently,
also in population-based studies (3). An-
other frequent sleep disorder, insomnia,
which is defined as a subjective feeling of
having difficulties initiating or maintaining
sleep or having a feeling of nonrestorative
sleep (4), has also been linked to impaired
glucose metabolism (5,6).
Most previous work has used the
HOMA of insulin resistance and some-
times the HOMA of b-cell function to
estimate fasting insulin resistance and
secretion, respectively (6,7). These
methods are clearly limited in the set-
ting of progressive insulin resistance
and may be particularly limited in older
adults, in whom peripheral insulin resis-
tance is prevalent. Potentially better
measures of insulin sensitivity and se-
cretion can be derived from an oral glu-
cose tolerance test (OGTT) (8,9). Little
research has been done on sleep disor-
ders and glucose metabolism using
these potentially more refined mea-
sures of insulin sensitivity and secretion.
Recent data indicate that both SDB
and insomnia symptoms are highly prev-
alent in patients with type 2 diabetes
(10–12). Fewer studies have assessed
the prospective association between
these sleep disorders and the incidence
of type 2 diabetes (13,14), and these have
mainly focused on young or middle-aged
adults.
Accordingly, we aimed to address sev-
eral gaps in the literature, as follows: 1)
to focus on an elderly cohort in whom
there are limited data on sleep disor-
ders, glucose metabolism, and type 2 di-
abetes; 2) to use longitudinal measures
of glucose metabolism; and 3) to con-
sider symptoms of both SDB and insom-
nia, both of which are common in older
populations.
RESEARCH DESIGN AND METHODS
Participant Recruitment
Between 1989 and 1990, a cohort of
5,201 participants was recruited from
Forsyth County, North Carolina; Sacra-
mento County, California; Washington
County, Maryland; and Pittsburgh,
Pennsylvania. The cohort was identified
using Medicare eligibility lists of the
Health Care Finance Administration.
Participants had to be $65 years of
age, ambulatory and community dwell-
ing, expected to remain in their commu-
nities for 3 years, and able to provide
personal informed consent (15). In
1992–1993, an additional 687 predom-
inantly African American participants
were recruited, for a total of 5,888
participants.
Interviews and Clinical Examinations
Participants were contacted every 6
months, alternating between telephone
interviews and visits to field centers,
from 1989–1990 through 1998–1999.
Sociodemographics (i.e., sex, age, race,
marital status, and number of years of
education completed), personal habits
(i.e., smoking, alcohol consumption,
and physical activity), and depressive
symptoms were collected by question-
naires. Participants reported their usual
frequency of consumption of beer,
wine, and liquor, and the usual number
of drinks consumed on each occasion,
from which the number of drinks per
week of alcoholic beverages was calcu-
lated. Physical activity (in kilocalories
per week) was collected using a modi-
fied Minnesota Leisure-Time Activities
questionnaire (16). Symptoms of de-
pression were collected using the mod-
ified Center for Epidemiologic Studies
Depression scale of 0–30 (17).
The participants were also asked
about their medical history, and reported
cardiovascular events (i.e., myocardial in-
farction and congestive heart failure
[CHF]) were verified from objective infor-
mation obtained from hospital and physi-
cian records, as previously described (18).
Each year, participants reported whether
they used over-the-counter sleeping pills
at least weekly.
Study staff measured height, waist
circumference, weight, and blood pres-
sure at study examinations. BMI was cal-
culated as weight (in kilograms) divided
by height squared (in meters). Systolic
blood pressure was measured twice,
and the average of the two was used
in the analyses. Cognitive impairment
was assessed using the Digit Symbol
Substitution Test (19). Medication
use was assessed at baseline and
annually from a validated medication
inventory (20).
Sleep Symptoms
Participants were asked whether any-
one had observed them having episodes
where they stopped breathing for a
while and then snorted or snored loudly,
which we term “observed apnea.” They
were also asked whether their spouse or
roommate had complained about their
loud snoring, labeled “bothersome
snoring,” andwhether they were usually
sleepy in the daytime, labeled “daytime
sleepiness.”
In addition, the participants reported
on the following three insomnia symp-
toms: whether they usually had diffi-
culties falling asleep, labeled “sleep
initiation problems”; experienced fre-
quent nightly awakenings, labeled
“sleep maintenance problems”; or usu-
ally woke up too early without being
able to go back to sleep, labeled “early
morning awakenings.” The response op-
tions on all sleep questions were “yes,”
“no,” and “I don’t know.” The partici-
pants were asked these questions an-
nually from 1989–1990 to 1993–1994.
Within a subgroup of Cardiovascular
Health Study (CHS) participants who at-
tended the Sleep Heart Health Study
(SHHS) (21), we validated the self-
reported SDB symptoms in the CHS
against the objectively measured sleep
variables in the SHHS. We compared the
median values of objectively measured
SDB in the participants reporting to have
SDB symptoms. In the subgroup of
;1,000 participants, we found higher
obstructive apnea-hypopnea index val-
ues, defined as all desaturations of
$4%, among those participants reporting
observed apnea (8.7 desaturations/h)
compared with those without observed
apnea (7.2 desaturations/h, P = 0.05),
and among those reporting bother-
some snoring (8.8 desaturations/h)
compared with those without bother-
some snoring (4.8 desaturations/h, P ,
0.001). We also found increasing ob-
structive apnea-hypopnea index values
with increasing number of SDB symp-
toms. The participants reporting day-
time sleepiness in the CHS had a
higher Epworth sleepiness score in the
SHHS compared with those without
daytime sleepiness in the CHS (median
9 and 6, respectively; P , 0.001). The
insomnia symptoms in the CHS were
also compared with the objectively
measured sleep latency (i.e., in mi-
nutes) and sleep efficiency, defined as
care.diabetesjournals.org Strand and Associates 2051
the percentage of time scored as sleep dur-
ing the sleepperiod, in the SHHS.We found
that participants with sleep initiation prob-
lems had longer sleep latency (18.8 min)
than those who did not report such prob-
lems (16.8 min, P = 0.14) and that those
reporting problems with sleep mainte-
nancehad lower sleepefficiency than those
without such problems (79.1% and 83.3%,
respectively; P,0.001). Those participants
with early morning awakenings had less
time in bed (7min, P = 0.03) and a shorter
total sleep time (11 min, P = 0.01) than
those without this symptom.
Glycemic Outcomes
An OGTT was performed in 1989–1990.
The venipuncture was performed in the
morning during the visit after an over-
night fast, and serum glucose levels
were measured (Kodak Ektachem 700
Analyzer; Eastman Kodak, Rochester,
NY) (22). After the fasting venipuncture,
75 g of glucose was given orally to con-
senting nondiabetic participants. A sec-
ond venipuncture was performed 2 h
later to obtain a 2-h glucose value. Fast-
ing serum glucose levels were measured
again in 1992–1993, 1994–1995 (non-
fasting), 1996–1997, and 1998–1999.
Supplementary Fig. 1 shows the time-
line for the collection of sleep symptoms
and the glycemic outcomes.
We estimated insulin sensitivity using
the Gutt index (Gutt et al. [8]), and in-
sulin secretion using the Stumvoll index
(Stumvoll et al. [9]).
Incident type 2 diabetes was defined
as new use of insulin or a hypoglycemic
agent, a fasting glucose level of $7.0
mmol/L, or a nonfasting glucose level
of $11.1 mmol/L.
Statistical Analysis
For descriptive purposes, we provide
the clinical characteristics of partici-
pants according to daytime sleepiness,
which is a potential consequence of ei-
ther SDB or insomnia. We calculated the
PearsonF coefficient to assess the rela-
tionships between the dichotomous
sleep variables.Missing data on baseline
covariates were imputed using methods
described previously (23).
Using linear regression, we analyzed
the cross-sectional associations of sleep
symptoms with 2-h glucose levels and
measures of insulin sensitivity and insu-
lin secretion in 3,007 participants with
information on sleep symptoms and
glucose measurements, and without
prevalent diabetes or CHF, who were
enrolled into the study in 1989–1990.
For cross-sectional analyses of fasting
glucose, we combined the 3,007 mea-
surements from 1989–1990 with 2,378
measurements from 1992–1993 (pro-
viding repeated measurements in the
original cohort and incorporating the
added African American cohort). We fit
generalized estimating equation models
with an identity link function and un-
structured within-group correlation.
Since not all included participants at-
tended both measurements, we had
5,385 observations from a total of
3,797 participants after excluding par-
ticipants with missing sleep symptoms
or glucose values, and those with prev-
alent diabetes or CHF. The participant
selection process is illustrated in Supple-
mentary Fig. 2.
Wenext usedCox proportional hazards
models to examine the associations of
sleep symptoms with the subsequent
risk of incident type 2 diabetes, estimat-
ing hazard ratios (HRs) and95%CIs. Of the
5,888 enrolled participants, 3,528 partic-
ipants were free of diabetes and CHF at
baseline and were included in the analy-
ses (Supplementary Fig. 3). The subjects
stopped contributing person-time to the
analyses when they received a diagnosis
of type 2 diabetes or at the time of the
last attended visit. We used the exact
marginal method to handle ties.
We allowed the sleep variables to
vary yearly (i.e., to be time dependent)
to examine current effects. In some par-
ticipants, the SDB symptoms resolved,
but we do not have information about
why this was the case. To examine the
difference in risk between current and
chronic symptoms, we reran the analy-
ses by calculating the cumulative aver-
age of previous values of the sleep
variables (0 or 1) each year and updating
them in the model. Because waist cir-
cumference is a particularly strong risk
factor for type 2 diabetes (24), we also
allowed waist circumference to change
over time in the same manner. We
replaced each missing value of the
time-dependent variables by the last
observed value of that variable. We re-
stricted our follow-up to 1998–1999, as
this was the last year that fasting glu-
cose levels were measured.
First, we ran separate models for ob-
served apnea, bothersome snoring, and
daytime sleepiness. Since observed ap-
nea and bothersome snoring are fre-
quently used as markers for SDB (14)
and daytime sleepiness is a potential
SDB consequence, we assessed their
joint associations by creating a cumula-
tive variable coded “0” for no symp-
toms, “1” for having one symptom,
and “2” for two or more symptoms.
Too few participants reported all three
symptoms (n = 63) to be categorized
separately. We treated insomnia symp-
toms similarly, first analyzing them sep-
arately and then combining symptoms
into a cumulative variable based on
the number of symptoms reported.
Since daytime sleepiness also is a conse-
quence of insomnia, we included it in
the combined variable.
We adjusted for covariates in two
multivariable models. In the first model,
we adjusted for age, sex, race, waist cir-
cumference, and clinic site (Model 1). In
the second model, we further adjusted
for marital status (never married, mar-
ried, separated/divorced/widowed); ed-
ucation (,12 years, 12 years, and 13+
years); smoking (never smoker, previous
smoker, current smoker); alcohol con-
sumption (,1 drink, 1–6 drinks, and
$7 drinks); BMI; physical activity; de-
pressive symptoms score; cognitive
function; systolic blood pressure; anti-
hypertensive medication use; levels of
creatinine, albumin, and total choles-
terol; and previous myocardial infarc-
tion (Model 2). In the analysis of the
insomnia symptoms, we also adjusted
for observed apnea; adjustment for ob-
served apnea in analyses of SDB symp-
toms did not meaningfully alter their
association with diabetes.
Those individuals living alone may be
less likely to report sleep apnea or snor-
ing, and we therefore excluded those
participants living alone in a sensitivity
analysis. Because of the association be-
tween SDB and insomnia, we also
excluded those participants with ob-
served apnea in another sensitivity
analysis. We also conducted several pre-
specified stratified analyses to assess
whether the associations of the sleep
disorders with glucose metabolism and
incident type 2 diabetes were modified
by other factors. We stratified by sex,
age (dichotomized at age 75 years), BMI
(dichotomized at 30 kg/m2), waist circum-
ference (dichotomized at 95 cm), and race.
We tested for multiplicative interaction
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across strata with relevant cross-product
terms. Because sleepdisorders are strongly
associated with chronic diseases, we ex-
cluded those participants with prevalent
heart disease.
To examine whether the use of sleep
medications changed the association
between the sleep symptoms and type
2 diabetes, recognizing that it may be a
cause or a consequence of sleep symp-
toms, we adjusted for this in separate
sensitivity analyses. We tested the pro-
portionality of hazards using log-log
curves and tests of interaction with
time and found no violations. We con-
ducted all statistical analyses using Stata
12 for Windows (Stata Corp., College
Station, TX).
RESULTS
The characteristics of participants ac-
cording to reported daytime sleepiness
are presented in Table 1. Participants
with daytime sleepiness tended to be
older, heavier, less physically active,
less educated, and more depressed,
and to have higher blood pressure.
They also had a higher prevalence of
observed apnea, bothersome snoring,
and all three insomnia symptoms. Sup-
plementary Table 1 shows the correla-
tions among the sleep variables.
Glucose Metabolism
None of the individual SDB symptoms
were associated with fasting glucose in
the cross-sectional analyses (Table 2).
There was, however, a graded trend to-
ward increased fasting glucose levels
with an increasing number of SDB symp-
toms. Participants experiencing daytime
sleepiness had higher 2-h glucose levels
than participants without this symptom,
and the 2-h glucose level was much
higher with an increasing number of
SDB symptoms.
Sleep initiation problems and sleep
maintenance problems were associated
with lower fasting glucose levels com-
pared with those levels in participants
who did not report these symptoms.
The cumulative number of insomnia
symptoms was also associated with
lower fasting glucose levels in a linear
fashion (P for trend = 0.003). However,
we found no consistent association of
any of these insomnia symptoms with
2-h glucose levels.
We then examined insulin sensitivity
and secretion (Table 3). We found lower
insulin sensitivity associated with each of
the SDB symptoms,with an inverse graded
relationship between the number of
symptoms and insulin sensitivity. We
found similar corresponding results with
SDB symptoms and greater insulin secre-
tion. We found no clear association be-
tween insomnia symptoms and insulin
sensitivity or insulin secretion, except for
an association of sleepmaintenance prob-
lems with increased insulin secretion.
Incident Type 2 Diabetes
Among the 3,528 participants, type 2 di-
abetes developed in a total of 208 partic-
ipants during a mean follow-up time of
5.1 years. Table 4 presents the adjusted
HRs and 95% CIs for incident diabetes in
relation to time-dependent symptoms of
SDB and insomnia, and their cumulative
average. Participants reporting observed
apnea, bothersome snoring, or daytime
sleepiness had increased risks of the de-
velopment of type 2 diabetes during the
follow-up compared with those who did
not report these symptoms. The time-
dependent observed apnea was more
strongly associated with incident type 2
diabetes than the cumulative average ob-
served apnea. The cumulative number of
SDB symptoms was also associated with
increased risk of incident type 2 diabetes.
We found no evidence of an associa-
tion for any of the insomnia symptoms
with incident type 2 diabetes.
Additional Analyses
Restricting the analysis to those partici-
pants not living alone and to those with-
out observed apnea or heart disease did
not change the results considerably (data
not shown).Wealso did not find evidence
of effect modification by age, sex, race,
BMI, or waist circumference.
The association of the sleep variables
with glucose metabolism and type 2 dia-
betes risk did not change after adjustment
for the use of sleep medications. For ex-
ample, in Model 2, among those partici-
pants having two or more SDB symptoms,
the estimated 2-h glucose level was
0.39 mmol/L (95% CI 0.09–0.67) higher
Table 1—Characteristics of the participants according to daytime sleepiness (yes/
no)
Variable
Daytime sleepiness (N = 3,528)
No
(n = 2,993)
Yes
(n = 535) P value
Age (years) 72.1 (5.3) 73.6 (5.8) ,0.001
Waist circumference (cm) 92.7 (12.6) 94.7 (13.3) ,0.001
Systolic blood pressure (mmHg) 138.1 (19.7) 141.1 (20.8) 0.001
Physical activity (kcal/week) 1,963.4 (2,192.0) 1,476.8 (1,725.9) ,0.001
BMI (kg/m2) 26.1 (4.3) 26.8 (5.0) 0.01
Depression score 4.0 (4.2) 6.2 (5.0) ,0.001
Creatinine (mmol/L) 92 (25) 96 (30) 0.001
Albumin (g/dL) 40.0 (2.9) 39.8 (2.9) 0.02
Total cholesterol (mmol/L) 5.6 (1.0) 5.5 (1.0) 0.24
Digit symbol substitution test score 38.3 (13.0) 33.3 (14.0) ,0.001
Fasting glucose (mmol/L) 5.5 (0.5) 5.6 (0.6) 0.14
Male sex (%) 58.7 54.0 0.04
White race (%) 89.0 85.4 0.05
Current smokers (%) 11.5 13.1 0.13
Married (%) 75.0 70.5 0.02
Observed apnea (%) 7.2 12.0 ,0.001
Bothersome snoring (%) 21.8 33.1 ,0.001
Sleep initiation problems (%) 19.2 31.0 ,0.001
Sleep maintenance problems (%) 60.8 75.0 ,0.001
Early morning awakenings (%) 27.8 49.4 ,0.001
Heavy drinkers (%) 15.4 12.9 0.03
College graduate (%) 46.4 36.1 ,0.001
Use of antihypertensive medications (%) 41.5 44.3 0.22
Prevalent myocardial infarction (%) 7.1 6.5 0.63
Data are reported as mean (SD), unless otherwise indicated.
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than in those without any SDB symptoms,
and the HR for incident type 2 diabetes
was 1.93 (95% CI 1.29–2.87).
CONCLUSIONS
In this populationof older adultswhowere
free of type 2 diabetes at baseline, having
observed apnea, bothersome snoring, and
daytime sleepiness were associated with
increased fasting glucose levels, increased
2-h glucose levels, decreased insulin sensi-
tivity, and increased insulin secretion. Each
symptom of SDB was associated with an
increased risk of incident type 2 diabetes
in a time-dependent manner. When we
combined them in a cumulative manner
that suggested the presence of a more
severe SDB, the risk of incident type 2 di-
abetes increased with an increasing
number of symptoms. For the insomnia
symptoms, we did not find a consistent
associationwith glucosemetabolism or in-
cident type 2 diabetes, except for a fasting
glucose level, where experiencing fre-
quent awakenings through the night was
associated with a decreased fasting glu-
cose level. Surprisingly, there was also an
inverse linear association between the
numberof insomnia symptomsand fasting
glucose level.
Similar to our findings, recent cross-
sectional studies (7,25) have found SDB
to be associated with glucose intoler-
ance and insulin resistance. These stud-
ies have relied on HOMA of insulin
resistance and HOMA of b-cell function
derived from fasting glucose and in-
sulin measurements, while we used
the Gutt index and the Stumvoll index
to account for both fasting and 2-h glu-
cose measurements derived from an
OGTT. The Gutt index has been reported
(26) to be sensitive to changes in glu-
cose metabolism in individuals with
moderate-to-severe sleep apnea who
were treated with continuous positive
airway pressure.
Limited previous evidence of a pro-
spective association between SDB symp-
toms and incident type 2 diabetes exists,
and the studies have mainly been small
and not always sufficiently powered to
detect an association (27). Similar to
our findings, a study (28) objectively
measuring sleep apnea in .4,000 par-
ticipants who were 40–69 years of age
reported an HR for incident type 2 di-
abetes of 1.69 (95% CI 1.04–2.96) among
thoseparticipantswithmoderate-to-severe
nocturnal intermittent hypoxia. A large
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observational study (14) reported a rel-
ative risk of 2.25 (95% CI 1.71–2.40) for
regular snorers compared with nons-
norers in almost 70,000 women in the
Nurses’ Health Study cohort. This rela-
tive risk is slightly higher than that in our
sample, which may reflect the additional
adjustment for waist circumference in
our study or indicate that the relative
risk from snoring for the development
of type 2 diabetes may be lower in
older adults.
In accordance with our findings, a re-
cent study (5) reported increased rates
of impaired glucose tolerance in SDB pa-
tients, but not in insomnia patients.
However, a recent meta-analysis (13)
of 10 studies including.100,000 partic-
ipants found increased risks of the de-
velopment of type 2 diabetes of 1.57
(95% CI 1.25–1.97) and 1.84 (95% CI
1.39–2.43), respectively, for sleep initi-
ation and sleep maintenance problems.
The participants in our study were all
$65 years of age, and, as the amount
of sleep may decrease with age, even in
subjects without daytime sleepiness
(29), the causes and correlates of in-
somnia in the elderly may differ from
those in younger populations, possibly
explaining differences between study
findings.
We observed differences in associa-
tions once specific insomnia symptoms
were analyzed, with one analysis show-
ing a negative association of fasting
glucose levels with sleep maintenance
symptoms. This finding, as well as prior
research, points to the need to consider
each aspect of insomnia separately, as
the health implications of sleep onset,
sleep maintenance, and early morning
awakenings may differ.
Sleep disorders are not constant over a
lifetime (30), and this is the first prospec-
tive study to account for this by allowing
the sleep exposure to change in yearly
increments during the follow-up. The
effect of observed apnea when allowing
it to change over the follow-up period
appeared to be stronger compared
with using the cumulative average, in-
dicating that current or recent sleep dis-
ruption may be more important than
previous/chronic symptoms in the de-
velopment of type 2 diabetes. The ap-
parently stronger association of the
more recent exposure of observed
apnea is a new finding and needs to be
confirmed by further studies.
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The mechanisms that underlie our
findings are largely unknown, but some
have been suggested. Sleep deprivation,
caused by SDB or insomnia, has been
shown to increase the activity of orexin
neurons that may act as a link between
SDB and the metabolic effects (31).
Sleep deprivation can also cause in-
creased sympathetic nervous activity,
increasing the released levels of cortisol
and catecholamines, leading to reduced
insulin sensitivity and glucose tolerance
(32,33). The corresponding increase in
insulin secretion may lead to b-cell ex-
haustion and impaired secretory capac-
ity over time, resulting in diabetes.
Limitations
Despite its clear strengths, which in-
clude the population-based design in a
high-risk older population, the wide
range of covariates, the OGTT-based
measures of insulin sensitivity and
secretion, and the repeated measures
of multiple sleep symptoms, the study
also has important limitations.
We used self-reported measures of
sleep, which, while subjective, have
the advantage of ready clinical applica-
bility at low cost. The participants were
asked whether anyone had observed
them having episodes where they stop-
ped breathing for a while and then
snorted or snored loudly or complained
about loud snoring. Participants living
alone may not have this knowledge
and may have reported “no” rather
than the option offered of “I don’t
know.” Although objective measures of
SDB (i.e., polysomnography results) ex-
ist, subjectively reported breath cessa-
tion is among the best clinical predictors
of sleep apnea (34), and self-reported
snoring is a sensitive but less specific
measure (35). In a sensitivity analysis,
we restricted the analysis to those not
living alone, and this changed our esti-
mates minimally. However, objective
polysomnography data available in a
subset indicated that the symptoms an-
alyzed discriminated between groups
with and without SDB symptoms. Fur-
thermore, because misclassification be-
tween these symptoms and sleep apnea
is unlikely to be related to glucose or
insulin levels, our results may underes-
timate the true associations of sleep ap-
nea with hyperglycemia and insulin
resistance. The difference in sleep la-
tency between those reporting sleep ini-
tiation problems and those who did not
was only 2 min, but, as insomnia is de-
fined as a subjective feeling of having
difficulties falling asleep, remaining
asleep, or receiving restorative sleep
lasting at least 1 month and causing day-
time impairment (4); thus, such problems
are not ideally evaluated by polysom-
nography (36).
Table 4—Symptoms of SDB and insomnia and 10-year risk of incident type 2 diabetes
Events/person-time
(208/29,234)
Model 1 Model 2
HR 95% CI P value HR 95% CI P value
Daytime sleepiness 56/5,016
Time dependent 1.62 1.19–2.21 0.002 1.58 1.15–2.18 0.005
Cumulative average 1.63 1.09–2.42 0.02 1.56 1.03–2.36 0.04
Observed apnea 24/1,626
Time dependent 1.98 1.28–3.05 0.002 1.86 1.20–2.88 0.006
Cumulative average 1.54 0.90–2.64 0.12 1.44 0.84–2.48 0.19
Bothersome snoring 88/10,307
Time dependent 1.30 0.97–1.75 0.08 1.28 0.95–1.72 0.11
Cumulative average 1.36 0.96–1.93 0.09 1.33 0.93–1.90 0.12
SDB symptoms
1 82/10,572 1.37 1.00–1.87 0.05 1.34 0.98–1.84 0.07
2–3 40/3,034 2.12 1.44–3.13 ,0.001 2.00 1.35–2.98 0.001
Linear trend ,0.001 0.001
Sleep initiation problems 41/5,999
Time dependent 1.05 0.74–1.49 0.79 0.99 0.69–1.43 0.96
Cumulative average 1.03 0.69–1.54 0.88 0.94 0.61–1.43 0.77
Sleep maintenance problems 133/18,838
Time dependent 0.94 0.71–1.26 0.69 0.87 0.65–1.17 0.36
Cumulative average 0.92 0.66–1.28 0.61 0.84 0.60–1.18 0.33
Early morning awakenings 68/9,183
Time dependent 1.06 0.79–1.41 0.71 0.99 0.73–1.34 0.95
Cumulative average 0.95 0.68–1.33 0.76 0.87 0.61–1.24 0.43
Insomnia symptoms
1 79/10,240 1.18 0.83–1.69 0.36 1.14 0.80–0.64 0.48
2 49/6,899 1.07 0.72–1.60 0.73 0.95 0.62–1.43 0.79
3 22/3,238 1.13 0.68–1.88 0.63 0.98 0.57–1.67 0.94
4 4/903 0.71 0.25–1.98 0.51 0.57 0.20–1.62 0.29
Linear trend 0.95 0.42
SDB symptoms include daytime sleepiness, observed apnea, and bothersome snoring. Insomnia symptoms include sleep initiation problems, sleep
maintenance problems, early morning awakenings, and daytime sleepiness. Model 1, adjusted for age, sex, race, waist circumference, and clinic site.
Model 2, adjusted for age, sex, race, marital status, clinic site, education, systolic blood pressure, use of antihypertensive medications, physical
activity, smoking, alcohol use, BMI, waist circumference, depression score, creatinine levels, albumin levels, cholesterol levels, prevalent myocardial
infarction, digit symbol substitution test results, and observed apnea (for the insomnia symptoms, daytime sleepiness and bothersome snoring).
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Information about sleep duration was
not available in CHS. SDB and insomnia
are different conditions than short sleep
duration (37), and people with insomnia
symptoms could have normal or long
durations of sleep (38). Also, some peo-
ple with short sleep duration may not
have insomnia symptoms or daytime
sleepiness, as individuals vary substan-
tially in the duration of sleep that is
needed for restoration (39).
Observational studies inherently limit
causal inference. Although we adjusted
for several potential confounders in our
multivariable analyses, we cannot ex-
clude the possibility of uncontrolled
confounding behind the observed associ-
ations. However, any remaining con-
founder that is potentially able to
influence our results would need to be
strongly associatedwith both sleep symp-
toms and glucose metabolism, and gen-
erally be unrelated to the factors included
in our models. Several small interven-
tional studies (26,40) suggest that sleep
apnea therapy may improve insulin resis-
tance, supporting a causal relationship
between SDB and insulin resistance. Of
note, these interventional studies have
in general excluded older individuals.
Summary
In this population-based study of older
adults, having observed apnea, bother-
some snoring, and daytime sleepiness
were associated with impaired glucose
metabolism, insulin resistance, and
risk of incident type 2 diabetes. For ob-
served apnea, more recent exposure
tended to be more strongly associated
with subsequent risk of type 2 diabe-
tes than chronic exposure. The associa-
tions persisted after adjustment for
total and central adiposity, suggesting
that SDB may impair glucose metabo-
lism independent of body fat. In con-
trast to previous studies, we found no
consistent association between the
insomnia symptoms and glucose me-
tabolism or incident type 2 diabetes.
Further studies are needed to deter-
mine whether insomnia symptoms
affect the risk of incident type 2 diabe-
tes differently in older adults than in
younger adults.
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